Teva Recalls Leucovorin Calcium Injection Due to Sterility Concerns
Teva Pharmaceuticals is recalling Leucovorin Calcium for Injection because manufacturing areas exceeded microbial acceptance levels, compromising sterility assurance.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves a lack of sterility assurance in injectable products, which poses a significant risk of infection or serious injury.
Plain-English summary
Teva Pharmaceuticals USA is recalling Leucovorin Calcium for Injection, USP, 350 mg/vial, NDC 0703-5145-01. The recall involves 705,745 vials distributed nationwide in the USA and Puerto Rico. The product is labeled as Teva Parenteral Medicines, Inc., Irvine, CA, and manufactured by Teva Pharmaceuticals USA, Inc., North Wales, PA.
The recall was initiated due to a lack of assurance of sterility. According to the source, manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery. This condition led to a lack of sterility assurance for these sterile injectable products.
Healthcare providers and patients should stop using the affected lots and contact Teva Pharmaceuticals for further instructions. The specific lot numbers and expiration dates are listed in the recall documentation.
The recalled product
- Product
- Leucovorin Calcium for Injection, USP, 350 mg/vial, Rx only, labeled as a) Teva Parenteral Medicines, Inc., Irvine, CA 92618, and b) Manufactured By: Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, novaplus+, NDC 0703-5145-01.
- Manufacturer
- Teva Pharmaceuticals USA
- Category
- Drug — Injectable
- Affected units
- 705,745
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot # a) 31324653B
- exp. date 03/2021
- 31326066B
- exp. date 11/2021
- 31326428B
- exp. date 02/2022
- 31327949B
- exp. date 10/2022
- 31327995B
- 31328031B
- exp. date 11/2022
- 31328217B
- exp. date 12/2022
- 31328325B
- 31328425B
- exp. date 07/2021
- Lot # b) 31324480B
- exp. date 02/2021
- Lot # 31327396B
- exp. date 08/2022
Distribution
Part of a larger recall action
This product is one of 15 recalled by Teva Pharmaceuticals USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 15 products in this recall →Related recalls
Same manufacturer · Teva Pharmaceuticals USA
See all →- ModerateDoxylamine Succinate and Pyridoxine Hydrochloride Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2022-02-09
- LowPrescription Drug Recall: Mimvey Mislabeling by Teva Pharmaceuticals
FDA (Drugs) · 2022-02-09
- ModerateTretinoin Capsules 10 mg Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2022-02-09
- LowMimvey Estradiol/Norethindrone Prescription Drug Mislabeling Recall
FDA (Drugs) · 2022-02-09
- ModerateBrinzolamide Ophthalmic Suspension recalled for defective container caps
FDA (Drugs) · 2022-01-26
Same hazard · sterility
See all →- SevereRegeneron Recalls Libtayo Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-08-26
- SeverePrestige Recalls Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns
FDA (Drugs) · 2026-08-19
- SevereFDA Recalls ROHTO OPTIC GLOW Eye Drops Over Sterility Concerns
FDA (Drugs) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SevereROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29